SCHEMBL21064418

SCHEMBL21064418

CC(=O)N(C)CC12CC(C(F)(F)F)(C1)C2

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.31
CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17586251 0.83 CHRM1 (0.31) CHRM1
SCHEMBL17586264 0.76 CHRM1 (0.34) CHRM1
SCHEMBL17586262 0.75 CHRM1 (0.33) CHRM1
SCHEMBL17586265 0.72 CHRM1 (0.31) CHRM1
SCHEMBL17586252 0.70 CHRM1 (0.31) CHRM1
SCHEMBL17586256 0.68 P2RX7 (0.45) CHRM1
SCHEMBL21064421 0.68 ALDH1A1 (0.41) PDK2
SCHEMBL24497411 0.65
SCHEMBL30984016 0.63 CHRM1 (0.41) CHRM1
SCHEMBL14557305 0.62 CHRM1 (0.39) PDK2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3193855-B1 BICYCLIC COMPOUNDS RECURIUM IP HOLDINGS LLC (US) 2021-05-19 EP disclosed
US-10975035-B2 Bicyclic compounds RECURIUM IP HOLDINGS, LLC (US) 2021-04-13 US disclosed
US-20190233377-A1 BICYCLIC COMPOUNDS Zeno Royalties & Milestones, LLC 2019-08-01 US disclosed
US-10308609-B2 Bicyclic compounds Zeno Royalties & Milestones, LLC (US) 2019-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190233377-A1 BICYCLIC COMPOUNDS OPRK1, OPRM1, OPRL1 PDK2 802/4885CHRM1 1444/4885
US-10975035-B2 Bicyclic compounds OPRK1, OPRM1, OPRL1 PDK2 802/4885CHRM1 1444/4885
US-10308609-B2 Bicyclic compounds OPRK1, OPRM1, OPRL1 PDK2 802/4885CHRM1 1444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.